Strasbourg, France – 7 July 2026
Dreampath Diagnostics today announces that it has been acquired by Halma plc, the global group of life-saving technology companies.
Headquartered in Strasbourg, France, Dreampath is a provider of automated workflow solutions for anatomical pathology laboratories. It designs and supplies systems that help laboratories track, store and retrieve patient tissue samples accurately and efficiently throughout the diagnostic process. Its solutions replace largely manual workflows, improving sample traceability, reducing the risk of misidentification and supporting greater efficiency in a in a decisive part of the patient journey.
The acquisition strengthens Dreampath’s ability to accelerate commercial growth, extend their market reach, and pursue opportunities in adjacent markets through sustained investment and innovation. This provides the opportunity for Dreampath to continue evolving in line with its values and roadmap, while benefiting from the stability and support to accelerate growth and product development.
Dreampath will operate as a standalone company within Halma’s Healthcare Sector.
Marc Ronchetti, Group Chief Executive of Halma, said: “Dreampath is a high-quality business in a growing area of diagnostics, driven by increasing demand for better healthcare, more testing alongside new treatments, and rising rates of chronic disease as populations age. It strengthens our Healthcare Sector by adding complementary capabilities and broadening our portfolio of technologies that support safer, more efficient and effective care. We are pleased to welcome Dreampath to Halma.”
Pablo Jordan, CEO of Dreampath, said: “We are excited to join Halma at an important point in Dreampath’s journey. We were looking for a long-term home that would value what makes Dreampath distinctive, support our people and culture, and help us accelerate our growth to continue protecting patients, sample by sample. Halma offers that combination of autonomy, ambition and support. We are pleased to become part of the Group and look forward to the opportunities ahead. We thank all employees, our shareholders and Summit for their support getting us here.”
About Halma
Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.
Its purpose defines the three broad market areas where it operates:
- Safety: Protecting people, assets and critical infrastructure by addressing safety risks in public, commercial and industrial environments, and supporting a safer, more sustainable future.
- Environmental & Analysis: Monitoring the environment and ensuring the quality and availability of life-critical resources, and enabling scientific research through advanced measurement, analysis and data transmission.
- Healthcare: Meeting the growing demand for healthcare as populations age and chronic conditions rise, by supporting the discovery of new cures, the prevention, diagnosis and treatment of patient conditions, and enabling the delivery of safer, more efficient healthcare.
It employs over 9,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.
Halma has been named as one of Britain’s Most Admired Companies for the past seven years.
For more information see www.halma.com
About on Dreampath Diagnostics
Dreampath Diagnostics is a France-based specialist in automated workflow solutions for anatomical pathology laboratories. Founded in 2012 and headquartered in Strasbourg, it designs and supplies systems that help laboratories track, store and retrieve patient tissue samples accurately and efficiently throughout the diagnostic process. Its solutions improve sample traceability, reduce manual handling and support reliable diagnosis in a highly regulated part of healthcare. www.dreampathdx.net.
